Navigation Links
Asymmetrex Describes How New Technologies for Quantifying Stem Cell Dosage Will Improve the Effectiveness of the Stem Cell Clinical Trial Supply Chain
Date:3/27/2021

The 2021 Virtual Conference on Clinical Trial Supply-Europe, organized by Arena International, started yesterday, March 24, and is continuing through today. More and more, clinical trial supply conferences are featuring speakers and forums that address the growing number of stem cell clinical trials. Stem cell biotechnology company Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk with this perspective on the opening day of the conference.

Sherley began his talk by highlighting the large and growing market for the supply of stem cell clinical trials, estimated to be about $10B in 2020 and projected to grow to $20B by 2027. The significant size of this supply chain market is indicative of the rapid growth of the stem cell clinical trials industry that depends on it.

Sherley’s presentation disclosed how a long-standing knowledge gap in stem cell medicine currently limits the effectiveness of the stem cell clinical trial supply chain. He discussed how the need for a means to quantify therapeutic tissue stem cells undermines the quality of every step of the supply chain. In previous Arena International clinical trials supply conferences, Sherley has discussed how the same need compromises the effectiveness of stem cell clinical trials themselves.

The main purpose of the presentation was to continue Asymmetrex’s efforts to introduce the stem cell clinical trial supply chain industry, and stem cell medicine in general, to emerging technologies that address the unmet need for a method to quantify the dosage of therapeutic stem cells. He emphasized that, “If dose is an essential principle in medicine, then it is also an essential requirement in stem cell medicine.”

In his talk, Sherley related how, recently, the FDA has been increasing attention on the problem of unknown cell-specific doses – which translates as stem cell-specific doses – in cellular therapies; and these developments were motivated in part by the emergence of new technologies for accurate determination of the dosage of therapeutic tissue stem cells. Asymmetrex’s business model is ending this current knowledge gap to increase the effectiveness of stem cell clinical trials and the growing industry that supplies them.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The company’s U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation therapies and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

Read the full story at https://www.prweb.com/releases/asymmetrex_describes_how_new_technologies_for_quantifying_stem_cell_dosage_will_improve_the_effectiveness_of_the_stem_cell_clinical_trial_supply_chain/prweb17824735.htm.


'/>"/>
Source: PRWeb
Copyright©2021 Vocus, Inc.
All rights reserved


Related biology news :

1. Asymmetrex’s Plan for Free Stem Cell Counting Is The Feature Story by Superb Crew News
2. Asymmetrex Announces Plans to Provide Free Tissue Stem Cell Counting
3. Asymmetrex Announces New Algorithms for Rapid Low Cost Counting of Therapeutic Tissue Stem Cells
4. Asymmetrex Partners in Manufacturing USA Institute
5. New Podcast Sponsored by Asymmetrex Increases Awareness to the Need for Stem Cell Dose in Stem Cell Treatments
6. Asymmetrex Approved to Conduct an ASTM Interlaboratory Evaluation of Its AlphaSTEM Test™ Technology as a Standard for Counting Therapeutic Adult Tissue Stem Cells
7. Asymmetrex Presents Proposal for ASTM Interlaboratory Evaluation of AlphaSTEM Test™ Technology Towards Establishing A Standard for Counting Therapeutic Stem Cells
8. Asymmetrex Publishes Chapter Explaining the Critical Need for Stem Cell Dosing for Success in Stem Cell Medicine
9. Asymmetrex Suggests a Stemgene Relief from Recent Cancer Woes About CRISPR-Cas9 Gene-Editing Therapies
10. Asymmetrex Proposes “Stemgene Therapy” to Emphasize the Importance of Tissue Stem Cells for Successful Gene Therapy
11. Dr. Atsuhiko (Ash) Toyama, PhD at Shimadzu Corporation Describes the Rationale Behind the Q-TOF LC/MS that Sufficiently Sustains Sub-PPM Mass Accuracy in Webinar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology: